Polymorphonuclear leukocyte: Rheology, metabolism and integrin pattern in vascular atherosclerotic disease and in type 2 diabetes mellitus

Clinical Hemorheology and Microcirculation

Volumn 30, Issue 3-4, 2004, Pages 229-235

  Caimi, G ^a,b   Lo Presti, R ^a   Montana, M ^a   Carollo, C ^a   Amodeo, G ^a   Romano, A ^a   Canino, B ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ATHEROSCLEROSIS; CALCIUM CELL LEVEL; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FLOW CYTOMETRY; FLOW KINETICS; FLUORESCENCE; HUMAN; LEUKOCYTE ACTIVATION; LEUKOCYTE FUNCTION; MALE; MEMBRANE FLUIDITY; METABOLISM; NEUTROPHIL; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; POLYMORPHONUCLEAR CELL; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE;

ANTIGENS, CD18; ARTERIOSCLEROSIS; CALCIUM; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; MALE; MEMBRANE FLUIDITY; MIDDLE AGED; NEUTROPHILS; REFERENCE VALUES; RHEOLOGY;

EID: 3242672289     PISSN: 13860291     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. E. Ernst, D.E. Hammerschmidt, U. Bagge, A. Matrai and J.A. Dormandy, Leukocytes and the risk of ischemic diseases, JAMA 257 (1987), 2318-2324.
2. J.A. Colwell and M.F. Lopes-Virella, A review of the development of large-vessel disease in diabetes mellitus, Am. J. Med. 85 (1988), 113-118.
3. G. Caimi, R. Lo Presti, M. Montana, B. Canino, G. Ventimiglia, G. Grifò, A. Catania and A. Sarno, Rheological and metabolic leucocyte determinants in diabetes mellitus, Clin. Hemorheol. 15 (1995), 53-60.
4. 2+ content after chemotactic activation, Clin. Hemorheol. 16 (1996), 523-531.
5. 2+ content in subjects with vascular atherosclerotic disease with and without noninsulin-dependent diabetes mellitus, Angiology 47 (1996), 757-763.
6. 2+ content in subjects with vascular atherosclerotic disease, Artery 22 (1997), 328-335.
7. 2+ content after activation in diabetes mellitus, Diabetes Nutr. Metab. 11 (1998), 237-241.
8. 2+ content after activation, Horm. Metab. Res. 30 (1998), 72-76.
9. G. Caimi, M. Montana, R. Citarrella, F. Porretto, A. Catania and R. Lo Presti, Polymorphonuclear leukocyte integrin profile in diabetes mellitus, Clin. Hemorheol. Microcirc. 27 (2002), 83-89.
10. G. Caimi, M. Montana, F. Ferrara, F. Porretto, M. Musso, B. Canino and R. Lo Presti, Polymorphonuclear leukocyte integrin pattern, at baseline and after activation, in type 2 diabetic subjects with macrovascular complications, Acta Diabetol. 40 (2003), 14-19.
11. R. Lo Presti, B. Canino, M. Montana, F. Ferrara, C. Carollo, F. Porretto and G. Caimi, Polymorphonuclear leukocyte integrin profile in vascular atherosclerotic disease, Clin. Hemorheol. Microcirc., in press.
12. P.W. Marks and F.R. Maxfield, Local and global changes in cytosolic free calcium in neutrophils during chemotaxis and phagocytosis, Cell Calcium 11 (1990), 181-190.
13. E. Carafoli, Calcium pump of the plasma membrane, Physiol. Rev. 71 (1991), 129-153.
14. J. Mikita, G. Nash and J. Dormandy, A simple method of preparing white blood cells for filterability testing, Clin. Hemorheol 6 (1986), 635-639.
15. S.E. Lennie, G.D.O. Lowe, J.C. Barbenel, C.D. Forbes and W.S. Foulds, Filterability of white blood cell subpopulations, separated by an improved method, Clin. Hemorheol. 7 (1987), 811-816.
16. J. Dormandy, P. Flute, A. Matrai, L. Bogar, J. Mikita, G.D.O. Lowe, J. Anderson, S. Chien, E. Schmalzer and A. Herschenfeld, The new St. George's blood filtrometer, Clin. Hemorheol. 5 (1985), 975-983.
17. M. Donner, S. Muller and J.F. Stoltz, Molecular rheology of white blood cells, Rev. Port. Hemorreol. 3 (1989), 235-247.
18. M.W. Roe, J.J. Lemasters and B. Herman, Assessment of Fura 2 for measurements of cytosolic free calcium, Cell Calcium 11 (1990), 63-73.
19. 2+-indicator fura-2, Cell Calcium 9 (1988), 167-179.
20. K. Yasui, M. Masuda, T. Matsuoka, M. Yamazaki, A. Komiyama, T. Akabane, M. Hasui, Y. Kobayashi and K. Murata, Abnormal membrane fluidity as a cause of impaired dynamics of chemoattractant receptors on neonatal polymorphonuclear leukocytes: lack of modulation of the receptors by a membrane fluidizer, Pediatr. Res. 24 (1988), 442-446.
21. M. Masuda, Y. Komiyama, T. Murakami, K. Murata, M. Hasui, Y. Hirabayashi and Y. Kobayashi, Difference in changes of membrane fluidity of polymorphonuclear leukocytes stimulated with phorbol myristate acetate and formyl-methionyl-leucyl-phenylalanine: role of excited oxygen species, J. Leukoc. Biol. 47 (1990), 105-110.
22. Z. Pecsvarady, T.C. Fisher, C.H. Darwin, A. Fabok, T.S. Maqueda, M.F. Saad and H.J. Meiselman, Decreased polymorphonuclear leukocyte deformability in NIDDM, Diabetes Care 17 (1994), 57-63.
23. T. Aversano, W. Zhou, M. Nedelman, M. Nakada and H. Weisman, A chimeric IgG4 monoclonal antibody directed against CD18 reduces infarct size in a primate model of myocardial ischemia and reperfusion, J. Am. Coll. Cardiol. 25 (1995), 781-788.
24. M. Arai, D.J. Lefer, T. So, A. DiPaula, T. Aversano and L.C. Becker, An anti-CD 18 antibody limits infarct size and preserves left ventricular function in dogs with ischemia and 48-hour reperfusion, J. Am. Coll. Cardiol. 27 (1996), 1278-1285.
25. P. Golino, G. Ambrosio, M. Ragni, P. Cirillo, N. Esposito, J.T. Willerson, R. Rothlein, L. Petrucci, M. Condorelli, M. Chiariello and L.M. Buja, Inhibition of leukocyte and platelet adhesion reduces neointimal hyperplasia after arterial injury, Thromb. Haemost. 77 (1997), 783-788.
26. H. Chen, M. Chopp, R.L. Zhang, G. Bodzin, Q. Chen, J.R. Rusche and R.F. Todd 3rd, Anti-CD11b monoclonal antibody reduces ischemic cell damage after transient focal cerebral ischemia in rat, Ann. Neurol. 35 (1994), 458-463.
27. M.A. Yenari, D. Kunis, G.H. Sun, D. Onley, L. Watson, S. Turner, S. Whitaker and G.K. Steinberg, Hu23F2G, an antibody recognizing the leukocyte CD11/CD18 integrin, reduces injury in a rabbit model of transient focal cerebral ischemia, Exp. Neurol. 153 (1998), 223-233.
28. K.W. Baran, M. Nguyen, G.R. McKendall, C.T. Lambrew, G. Dykstra, S.T. Palmeri, R.J. Gibbons, S. Borzak, B.E. Sobel, S.G. Gourlay, A.C. Rundle, C.M. Gibson, H.V. Barron; Limitation of Myocardial Infarction Following Thrombolysis in Acute Myocardial Infarction (LIMIT AMI) Study Group, Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study, Circulation 104 (2001), 2778-2783.
29. D.P. Faxon, R.J. Gibbons, N.A. Chronos, P.A. Gurbel, F. Sheehan; HALT-MI Investigators, The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study, J. Am. Coll. Cardiol. 40 (2002), 1199-1204.